Pavmed last week dramatically trimmed its pending initial public offering, saying it plans to float 1.2 million shares at $5 apiece for gross proceeds of $6 million. That’s a far cry from the $23 million top end Pavmed listed when it registered the IPO last May. Pavmed is developing devices in 5 areas, according to its […]